The goal of this study is to evaluate how safe and effective the new drug PRI-002 is for the treatment of participants with MCI or a mild form of dementia caused by Alzheimer’s disease. The study compares the effect of the new drug PRI-002 with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug is a capsule that is taken orally.

55 - 80 years

MCI or a mild form of dementia caused by Alzheimer’s disease

Approximately 1 to 2 years

Amsterdam, Den Bosch or Zwolle

The goal of this study is to evaluate how safe and effective the new drug BIIB080 is for the treatment of participants with mild to moderate Alzheimer’s disease. The study compares the effect of the new drug BIIB080 with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug is injected into the back.

50 - 80 years

Mild to moderate Alzheimer’s disease

Approximately 2 years

Amsterdam

The goal of this study is to evaluate how safe, tolerable and effective the new drug IBC-Ab002 is for the treatment of participants with early stage Alzheimer’s disease. The study compares the effect of the new drug IBC-Ab002 with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug is administered through an intravenous (IV) injection.

50-80 years

Early stage Alzheimer's disease

54 weeks

Amsterdam

The goal of this study is to evaluate how safe and effective the new drug GV1001 is for the treatment of participants with mild to moderate stage Alzheimer’s Disease. The study compares the effect of the new drug GV1001 with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug is administered through a subcutaneous injection.

55 - 85 years

Mild to moderate stage Alzheimer’s disease

58 weeks

Amsterdam, Den Bosch and Zwolle

The goal of this study is to evaluate how safe and effective the new drug CT1812 is for the treatment of participants with mild to moderate Alzheimer’s disease. The study compares the effect of the new drug CT1812 with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug is administered orally.

50 - 85 years

Mild to moderate Alzheimer’s disease

Approximately 9 months

Amsterdam, Den Bosch and Zwolle

The goal of this study is to evaluate how safe and effective the new drug TW001 is for the treatment of participants with early stage Alzheimer’s disease. The study compares the effect of the new drug TW001 with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug consists of granules which are dissolved in water.

55 - 80 years

Early stage Alzheimer's disease

Approximately 17 weeks

Amsterdam, Den Bosch and Zwolle